Literature DB >> 21945191

Expression profile of the sphingosine kinase signalling system in the lung of patients with chronic obstructive pulmonary disease.

Fabian Cordts1, Stuart Pitson, Christoph Tabeling, Ian Gibbins, David F Moffat, Hubertus Jersmann, Sandra Hodge, Rainer V Haberberger.   

Abstract

AIMS: Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. Despite its importance, treatment methods are limited and restricted to symptomatic care, highlighting the urgent need for new treatment options. Tissue damage in COPD is thought to result from an inability of the normal repair processes with accumulation of apoptotic material and impaired clearance of this material by macrophages in the airways. Lung inflammation involves the bioactive sphingolipid sphingosine 1-phosphate (S1P). MAIN
METHODS: We investigated lung tissue samples from 55 patients (25 with COPD) undergoing lobectomies for management of cancer. We analysed the sphingosine-kinase (SphK) mRNA expression profile, SphK enzyme activity as well as the localisation and expression of individual proteins related to the SphK-signalling system. KEY
FINDINGS: We show in this study for the first time a comprehensive expression profile of all synthesising enzymes, receptors and degrading enzymes of the SphK-signalling system in the human lung. Multivariate ANOVA showed that the relative mRNA expression of S1P receptor (S1PR) subtype 5 was reduced in COPD. There were strong positive correlations between the mRNA expression of S1PR5 and S1PR1 and S1PR3, and between S1PR3 and S1PR2. A significant negative correlation was found between S1PR1 and SphK protein activity. SIGNIFICANCE: The correlations between expression levels of receptors and enzymes involved in the sphingosine kinase signalling system in the lung suggest common regulatory mechanisms. Our findings of reduced S1PR5 in COPD and the correlation with other S1P receptors in COPD identify S1PR5 as a possible novel target for pharmacotherapy. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945191     DOI: 10.1016/j.lfs.2011.08.018

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  19 in total

1.  CFTR and sphingolipids mediate hypoxic pulmonary vasoconstriction.

Authors:  Christoph Tabeling; Hanpo Yu; Liming Wang; Hannes Ranke; Neil M Goldenberg; Diana Zabini; Elena Noe; Adrienn Krauszman; Birgitt Gutbier; Jun Yin; Michael Schaefer; Christoph Arenz; Andreas C Hocke; Norbert Suttorp; Richard L Proia; Martin Witzenrath; Wolfgang M Kuebler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-17       Impact factor: 11.205

2.  Plasma sphingolipids and lung cancer: a population-based, nested case-control study.

Authors:  Anthony J Alberg; Kent Armeson; Jason S Pierce; Jacek Bielawski; Alicja Bielawska; Kala Visvanathan; Elizabeth G Hill; Besim Ogretmen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-06-07       Impact factor: 4.254

3.  Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes.

Authors:  Russell P Bowler; Sean Jacobson; Charmion Cruickshank; Grant J Hughes; Charlotte Siska; Daniel S Ory; Irina Petrache; Jean E Schaffer; Nichole Reisdorph; Katerina Kechris
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

Review 4.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

5.  AIM2 nuclear exit and inflammasome activation in chronic obstructive pulmonary disease and response to cigarette smoke.

Authors:  Hai B Tran; Rhys Hamon; Hubertus Jersmann; Miranda P Ween; Patrick Asare; Rainer Haberberger; Harshita Pant; Sandra J Hodge
Journal:  J Inflamm (Lond)       Date:  2021-05-22       Impact factor: 4.981

6.  Ceramide and sphingosine-1 phosphate in COPD lungs.

Authors:  Evgeny V Berdyshev; Karina A Serban; Kelly S Schweitzer; Irina A Bronova; Andrew Mikosz; Irina Petrache
Journal:  Thorax       Date:  2021-01-29       Impact factor: 9.102

7.  Potential Link between the Sphingosine-1-Phosphate (S1P) System and Defective Alveolar Macrophage Phagocytic Function in Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Jameel Barnawi; Hai Tran; Hubertus Jersmann; Stuart Pitson; Eugene Roscioli; Greg Hodge; Robyn Meech; Rainer Haberberger; Sandra Hodge
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

8.  Zinc and zinc transporters in macrophages and their roles in efferocytosis in COPD.

Authors:  Rhys Hamon; Claire C Homan; Hai B Tran; Violet R Mukaro; Susan E Lester; Eugene Roscioli; Mariea D Bosco; Chiara M Murgia; Margaret Leigh Ackland; Hubertus P Jersmann; Carol Lang; Peter D Zalewski; Sandra J Hodge
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

9.  Defective lung macrophage function in lung cancer ± chronic obstructive pulmonary disease (COPD/emphysema)-mediated by cancer cell production of PGE2?

Authors:  Francis C Dehle; Violet R Mukaro; Craig Jurisevic; David Moffat; Jessica Ahern; Greg Hodge; Hubertus Jersmann; Paul N Reynolds; Sandra Hodge
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

10.  Sphingolipids: a potential molecular approach to treat allergic inflammation.

Authors:  Wai Y Sun; Claudine S Bonder
Journal:  J Allergy (Cairo)       Date:  2012-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.